Iothalamate Meglumine Injection
Click to View Image
C11H9I3N2O4·C7H17NO5 809.13

Benzoic acid, 3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]-, compd. with 1-deoxy-1-(methylamino)-d-glucitol (1:1).
1-Deoxy-1-(methylamino)-d-glucitol 5-acetamido-2,4,6-triiodo-N-methylisophthalamate (salt) [13087-53-1].
» Iothalamate Meglumine Injection is a sterile solution of Iothalamic Acid in Water for Injection, prepared with the aid of Meglumine. It contains not less than 95.0 percent and not more than 105.0 percent of the labeled amount of iothalamate meglumine (C11H9I3N2O4·C7H17NO5). It may contain small amounts of suitable buffers and of Edetate Calcium Disodium or Edetate Disodium as a stabilizer. Iothalamate Meglumine Injection intended for intravascular use contains no antimicrobial agents.
Packaging and storage— Preserve in single-dose containers, preferably of Type I glass, protected from light.
Labeling— Label containers of Injection intended for intravascular injection to direct the user to discard any unused portion remaining in the container. Label containers of Injection intended for other than intravascular injection to show that the contents are not intended for intravascular injection.
Identification— Dilute 3 mL of Injection with water to 100 mL, add an excess of 3 N hydrochloric acid, and filter. Wash the precipitated iothalamic acid on the filter with four 10-mL portions of water, and dry at 105 for 4 hours: the dried iothalamic acid responds to the following tests.
A: The IR absorption spectrum of a 0.5% potassium bromide dispersion of the dried acid exhibits maxima only at the same wavelengths as that of a similar preparation of USP Iothalamic Acid RS.
B: Heat about 500 mg of the dried acid in a suitable crucible: violet vapors are evolved.
Bacterial endotoxins 85 It contains not more than 0.9 USP Endotoxin Unit per mL.
pH 791: between 6.5 and 7.7.
Free aromatic amine— Dilute a suitable volume of Injection with water to yield a solution containing 100 mg of iothalamate meglumine per mL. Proceed as directed in the test for Free aromatic amine under Iothalamic Acid, beginning with “Pipet 5 mL of this solution into a 50-mL volumetric flask.”
Iodine and iodide— Dilute a volume of Injection, equivalent to 2 g of iothalamate meglumine, with 20 mL of water in a 50-mL beaker, add 5 mL of 2 N sulfuric acid, stir, and filter into a glass-stoppered, 50-mL cylinder. Proceed as directed for Procedure in the test for Iodine and iodide under Iothalamic Acid, beginning with “To the filtrate add 5 mL of toluene.”
Heavy metals 231 In a 50-mL color-comparison tube, mix a volume of Injection, equivalent to 1.0 g of iothalamate meglumine, with 5 mL of 1 N sodium hydroxide, dilute with water to 40 mL, and mix. Using this as the Test preparation, proceed as directed in the test for Heavy metals under Diatrizoate Meglumine: the limit is 0.002%.
Meglumine content— Proceed as directed in the test for Meglumine content under Diatrizoate Meglumine Injection. The meglumine content is not less than 22.9% and not more than 25.3% of the labeled amount of iothalamate meglumine.
Other requirements— It meets the requirements under Injections 1.
Assay— Pipet a volume of Injection, equivalent to about 4 g of iothalamate meglumine, into a 250-mL volumetric flask, dilute with water to volume, and mix. Pipet 25 mL of this solution into a glass-stoppered, 125-mL conical flask, add 12 mL of 5 N sodium hydroxide and 1 g of powdered zinc, connect the flask to a reflux condenser, and reflux for 30 minutes. Cool to room temperature, rinse the condenser with 20 mL of water, disconnect the flask from the condenser, and filter the mixture. Rinse the filter and the flask thoroughly, adding the rinsings to the filtrate. Add 40 mL of 2 N sulfuric acid, and titrate immediately with 0.05 N silver nitrate VS, determining the endpoint potentiometrically, using silver-calomel electrodes and an agar-potassium nitrate salt bridge. Each mL of 0.05 N silver nitrate is equivalent to 13.49 mg of C11H9I3N2O4·C7H17NO5.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Ian DeVeau, Ph.D.
Director, Veterinary Drugs and Radiopharmaceuticals
(RMI05) Radiopharmaceuticals and Medical Imaging Agents 05
Reference Standards Lili Wang, Technical Services Scientist
85 Radhakrishna S Tirumalai, Ph.D.
Senior Scientist
(MSA05) Microbiology and Sterility Assurance
USP32–NF27 Page 2674